Experimental rodent studies have shown that genetic and pharmacological inhibition of the NLRP3 inflammasome may reduce MI size and prevent adverse LV remodeling (Coll et al., 2015; Kawaguchi et al., 2011; Marchetti et al., 2014; Mezzaroma et al., 2011; Pomerantz et al., 2001; Sandanger et al., 2013). This evidence concerns the gene NLRP3 and myocardial infarction.